Lapatinib plus whole-brain radiotherapy may control brain metastases in HER2+ breast cancer

An investigation of the tyrosine kinase inhibitor lapatinib (Tykerb) plus whole-brain radiotherapy has entered into a phase II trial in the treatment of patients with brain metastases from HER2-positive breast cancer. The researchers are specifically evaluating the use of stereotactic radiosurgery in this setting, which is a specialised type of radiotherapy that delivers a single, high dose of radiation directly to the tumour.